Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Vandria SA has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is handled by 1 examiner in 1 art unit, so the prosecution record presents a single examination path.
WARD, PAUL V is the busiest examiner, with 1 pending matter. Counsel can focus preparation on the record before one examiner and the practices of one art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18226621 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | WARD, PAUL V | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18226621 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | WARD, PAUL V | 1622 | §102 | Non-Final OA | — | Pending | Jul 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVandria SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul V Ward has the most, with 1 of Vandria SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
